Eight researchers from Cambridge have raised a $129m patient capital fund that has attracted limited partners including Aviva.
Insurance provider Aviva has put its weight behind the £100m ($129m) Ahren Innovation Capital fund, co-founded by eight scientists from the Cambridge, UK ecosystem, the Financial Times reported today.
Diversified holding group Wittington Investments and undisclosed US families have also backed the fund, as have the eight researchers. Ahren expects to raise “substantially more” capital over the next few months.
Ahren was formed last year and is already operational, having led a $30m series C round for Cambridge Epigenetix, a…
